Can I Take Melatonin with GHK-Cu?

What Is GHK-Cu and How Does It Work?

GHK-Cu is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, bound to a copper(II) ion. It was first isolated from human plasma in 1973 by Loren Pickart and has since been studied for wound healing, skin remodeling, and anti-inflammatory activity. The peptide is not FDA-approved as a drug, but licensed compounding pharmacies operating under 503A and 503B frameworks may prepare it for individual prescriptions.

Mechanism at the Cellular Level

GHK-Cu binds copper and delivers it to cells in a bioavailable form, where it supports superoxide dismutase (SOD) activity and collagen synthesis. A 2018 review in Biomolecules by Pickart et al. Summarized evidence that GHK-Cu upregulates over 30 genes associated with tissue repair, including those encoding collagen types I and III, decorin, and transforming growth factor beta-1 1.

Antioxidant Profile

Independent of its copper-delivery function, GHK-Cu scavenges reactive oxygen species (ROS) and reduces lipid peroxidation. A study in Free Radical Biology and Medicine demonstrated that GHK inhibited iron-induced oxidative damage in rat brain tissue at concentrations as low as 1 micromolar 2. This antioxidant activity is the only mechanistic pathway it shares with melatonin.

Copper Metabolism Context

Copper homeostasis in the body is tightly regulated. Serum copper in healthy adults ranges from 70 to 140 mcg/dL, and ceruloplasmin carries approximately 90% of plasma copper. The National Institutes of Health Office of Dietary Supplements notes the tolerable upper intake level (UL) for copper in adults is 10 mg per day 3. Clinical doses of GHK-Cu peptide at 2 mg to 10 mg provide only a fraction of elemental copper within a much larger peptide molecule, meaning systemic copper load from GHK-Cu supplementation is small.

What Is Melatonin and How Does It Work?

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous indoleamine synthesized in the pineal gland primarily from serotonin. Secretion peaks between 2:00 a.m. And 4:00 a.m. And is suppressed by light exposure. The FDA classifies over-the-counter melatonin as a dietary supplement in the United States.

Receptor Pharmacology

Melatonin binds MT1 and MT2 receptors in the suprachiasmatic nucleus and peripheral tissues. MT1 activation suppresses neuronal firing and consolidates sleep onset; MT2 activation shifts circadian phase. Ramelteon, the prescription MT1/MT2 agonist, follows the same receptor mechanism at higher affinity. A 2013 Cochrane review (N=1,683 across 19 trials) found melatonin reduced sleep-onset latency by 7.06 minutes and increased total sleep time by 8.25 minutes versus placebo 4.

Antioxidant and Anti-inflammatory Actions

Beyond sleep regulation, melatonin is a broad-spectrum free-radical scavenger. It donates electrons directly to hydroxyl radicals and superoxide without requiring an enzymatic cofactor. A review in Journal of Pineal Research described melatonin and its metabolites as forming a "free radical scavenging cascade" capable of neutralizing up to four reactive species per melatonin molecule 5.

Metabolic Considerations

Melatonin affects glucose tolerance through MT1/MT2 receptors on pancreatic beta cells. A Mendelian randomization study published in JAMA (N=100,223 genetic proxies) found that genetically elevated melatonin signaling associated with higher fasting glucose and increased type 2 diabetes risk 6. Pharmacologic melatonin doses (5 mg to 10 mg) taken at night may transiently reduce insulin secretion. Persons with insulin resistance or type 2 diabetes using GHK-Cu as part of a metabolic protocol should note this and discuss timing with their prescribing clinician.

Is There a Known Drug Interaction Between GHK-Cu and Melatonin?

No published pharmacokinetic interaction study exists for this combination. The absence is not surprising. GHK-Cu is a peptide that is absorbed subcutaneously or transdermally; it does not significantly engage CYP450 hepatic enzymes. Melatonin is primarily metabolized by CYP1A2 in the liver. Because GHK-Cu is not a meaningful CYP1A2 inducer or inhibitor, it is unlikely to alter melatonin clearance.

Pharmacokinetic Analysis

Pharmacokinetic interactions occur when one compound changes the absorption, distribution, metabolism, or excretion of another. GHK-Cu's half-life after subcutaneous injection is short (estimated under 30 minutes based on peptide-degradation kinetics for similar tripeptides) 7. Melatonin's oral half-life is approximately 45 minutes with wide interindividual variation depending on CYP1A2 activity 8. These two compounds are processed through entirely separate routes. No evidence of altered plasma levels of either compound when co-administered has been published.

Pharmacodynamic Analysis

Pharmacodynamic interactions occur when two compounds produce additive, synergistic, or antagonistic effects on the same biological target. GHK-Cu and melatonin share only one overlapping pharmacodynamic territory: antioxidant activity. Both scavenge ROS, though via different molecular mechanisms. That overlap is more likely to produce a mild additive antioxidant benefit than any harm. No published case report or controlled trial documents antagonism between them.

The HealthRX clinical team uses a four-category interaction assessment for peptide-supplement co-administration:

| Category | Definition | GHK-Cu + Melatonin | |---|---|---| | 1. Pharmacokinetic | One alters metabolism/clearance of the other | Not detected | | 2. Pharmacodynamic (adverse) | Opposing or toxic combined action at shared target | Not detected | | 3. Pharmacodynamic (additive benefit) | Overlapping beneficial effect at shared target | Possible (antioxidant) | | 4. Indirect metabolic | One changes metabolic context that affects the other's efficacy | Low-risk (see glucose section) |

Based on currently available evidence, GHK-Cu plus melatonin falls into Category 3 only.

Timing and Dosing Guidance

Timing these two compounds is straightforward because they serve different physiological functions and have no interaction requiring separation.

Melatonin Timing

The American Academy of Sleep Medicine 2017 clinical practice guideline on pediatric sleep recommended doses between 0.5 mg and 5 mg taken 30 to 60 minutes before the target sleep time 9. For adults, the same 30-to-60-minute window applies. Starting at 0.5 mg and titrating upward minimizes morning grogginess; doses above 5 mg do not consistently improve sleep quality in healthy adults according to a systematic review by Brzezinski et al. In Sleep Medicine Reviews 10.

GHK-Cu Timing

Subcutaneous GHK-Cu injections are typically administered in the morning or evening depending on the protocol from the prescribing 503A compounding pharmacy. Topical GHK-Cu serums are applied to skin at whatever time suits the skincare routine. Neither administration window conflicts with pre-bedtime melatonin. If GHK-Cu is injected in the evening, allowing at least 15 to 30 minutes between injection and melatonin ingestion keeps the timing clean, though this is a practical preference rather than a clinical requirement.

Starting Doses in Context

Most compounding protocols for systemic GHK-Cu begin at 2 mg per injection, three to five times per week. Topical concentrations typically range from 0.1% to 1% in serums. Melatonin's most evidence-supported starting dose is 0.5 mg, which approximates the physiologic nighttime peak. Pharmacologic doses (3 mg to 10 mg) are widely sold over the counter but may cause morning sedation in some users.

Antioxidant Combination: Benefit or Concern?

The dual antioxidant activity of GHK-Cu and melatonin raises a reasonable question. Can over-suppression of ROS be harmful?

Why Excess Antioxidant Supplementation Can Backfire

High-dose antioxidant supplementation has a complicated track record. The ATBC trial found beta-carotene at 20 mg per day increased lung cancer incidence by 18% in male smokers (N=29,133) 11. That finding does not directly apply to GHK-Cu or melatonin, which work through different mechanisms and at much lower ROS-scavenging magnitudes. Still, it illustrates that antioxidant overload is a real biological concept.

Practical Implications for This Stack

At standard clinical doses of GHK-Cu (2 mg to 10 mg) and melatonin (0.5 mg to 5 mg), the combined antioxidant load is modest. No published data suggest this stack produces harmful ROS suppression. The concern about antioxidant excess is most relevant for very-high-dose vitamin C, vitamin E, or selenium supplementation, not for peptide-plus-melatonin combinations at the doses described here.

Special Populations and Precautions

Persons with Copper Metabolism Disorders

Wilson disease is an autosomal recessive disorder causing copper accumulation in the liver, brain, and other organs. Persons with Wilson disease should not use GHK-Cu without specialist guidance, regardless of any co-supplement. The European Association for the Study of the Liver (EASL) 2012 clinical practice guidelines state that copper-chelating therapy is the cornerstone of Wilson disease management, and any copper-providing compound is contraindicated 12.

Persons with Diabetes or Insulin Resistance

As noted in the melatonin pharmacology section, pharmacologic melatonin doses may transiently reduce insulin secretion at night via MT1/MT2 receptor activity on beta cells 6. Persons using GHK-Cu as part of a broader metabolic optimization protocol who also have type 2 diabetes should take melatonin at the lowest effective dose (0.5 mg to 1 mg) and discuss timing with their endocrinologist. GHK-Cu itself has no documented effect on insulin secretion.

Persons on CYP1A2-Sensitive Medications

Melatonin is a CYP1A2 substrate. Fluvoxamine, a potent CYP1A2 inhibitor, increases melatonin plasma levels by up to 17-fold 13. Smoking induces CYP1A2 and reduces melatonin exposure. GHK-Cu does not meaningfully affect CYP1A2 activity, so adding GHK-Cu to someone already on fluvoxamine plus melatonin does not compound the existing drug-drug interaction. The fluvoxamine-melatonin pair requires independent management.

Pregnancy and Lactation

Neither GHK-Cu nor pharmacologic melatonin has adequate safety data in pregnancy. The American College of Obstetricians and Gynecologists does not endorse melatonin supplementation during pregnancy 14. GHK-Cu is similarly unstudied in pregnancy. Both should be avoided unless specifically directed by an obstetrician.

Monitoring Recommendations

Lab Testing for Systemic GHK-Cu Users

Routine labs are not required for topical GHK-Cu users. For persons receiving systemic (subcutaneous) GHK-Cu on an ongoing basis, the HealthRX medical team recommends checking serum copper and ceruloplasmin at baseline and annually. Normal serum copper is 70 to 140 mcg/dL; ceruloplasmin reference range is 20 to 35 mg/dL 3.

Signs of Copper Excess

Symptoms of copper toxicity at acutely high doses include nausea, vomiting, abdominal pain, and in severe cases hepatic dysfunction. Chronic low-level copper excess is more subtle, presenting as fatigue and elevated liver enzymes. At the doses delivered by GHK-Cu peptide therapy (2 mg to 10 mg of peptide, not elemental copper), toxicity is unlikely in people with normal copper metabolism, but labs provide objective reassurance.

Melatonin-Specific Monitoring

No routine labs are required for melatonin at doses up to 10 mg in healthy adults. The supplement is renally cleared and does not accumulate. Persons with significant hepatic impairment should use lower doses because CYP1A2 metabolism may be reduced, elevating exposure.

What the Evidence Does Not Yet Tell Us

No head-to-head randomized controlled trial has examined GHK-Cu plus melatonin co-administration. The interaction analysis in this article is mechanistic inference from separately conducted studies, not direct human trial data. This is a meaningful limitation. Direct RCT evidence on GHK-Cu for any indication remains sparse; a PubMed search for "GHK-Cu randomized controlled trial" returns fewer than 10 indexed human trials as of early 2025, most in wound-healing and dermatology contexts. Research on GHK-Cu's systemic effects (metabolic, neurological) is largely preclinical.

Melatonin has a far richer clinical evidence base, with over 400 RCTs indexed on PubMed, but almost none specifically examine its combination with copper-based peptides. Anyone stacking these two compounds is doing so ahead of the direct human evidence, which is a relevant fact to weigh.